1-3 of 3
Christopher F. Mojcik, MD, PhD
Close
Sort by
Journal Articles

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

Jörg Schubert, MD, Peter Hillmen, MB, PhD, Ulrich Dührsen, DM, Neal S. Young, MD, Modupe Elebute, MB, MD, Jeffrey Szer, MB, BS, Giacomo Gianfaldoni, MD, Gérard Socié, MD, PhD, Paul Browne, MD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Petra Muus, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 124.
https://doi.org/10.1182/blood.V108.11.124.124
Published: 2006
Journal Articles

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Neal S. Young, MD, Elisabetta Antonioli, MD, Bruno Rotoli, MD, Hubert Schrezenmeier, MD, Jörg Schubert, MD, Alvaro Urbano-Ispizua, MD, Luke Coyle, MD, Carlos de Castro, MD, Chieh-Lin Fu, MD, Jaroslaw P. Maciejewski, MD, PhD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Peter Hillmen, MB PhD
Journal: Blood
Blood (2006) 108 (11): 971.
https://doi.org/10.1182/blood.V108.11.971.971
Published: 2006
Journal Articles

Successful Treatment of Hemolysis and Severe Anemia without Transfusion in a Jehovah’s Witness PNH Patient with the Terminal Complement Inhibitor Eculizumab.

Robert M. Glasser, MD, Christopher F. Mojcik, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 3768.
https://doi.org/10.1182/blood.V106.11.3768.3768
Published: 2005